West Pharmaceutical Servs Raises FY2026 Adj EPS Guidance from $7.85-$8.20 to $8.40-$8.75 vs $8.01 Est; Raises FY2026 Sales Guidance from $3.215B-$3.275B to $3.295B-$3.350B vs $3.249B Est
Benzinga Newsdesk 6 months ago
NewsGuidance
Outlook for Full-Year and Second Quarter 2026Full-year 2026 net sales guidance increased to a range of $3.295 billion to $3.350 billion, up from $3.215 billion to $3.275 billion and full-year 2026 adjusted-diluted EPS
Outlook for Full-Year and Second Quarter 2026
- Full-year 2026 net sales guidance increased to a range of $3.295 billion to $3.350 billion, up from $3.215 billion to $3.275 billion and full-year 2026 adjusted-diluted EPS guidance increased to a range of $8.40 to $8.75, up from $7.85 to $8.20.
- Second quarter 2026 net sales are expected to be in the range of $830 million to $850 million, up 8.3% to 10.9% reported and up 7.0% to 9.6% organic.